Cite

HARVARD Citation

    Matsubara, D. et al. (2021). Analysis of the long‐term economic burden of omalizumab on patients with chronic spontaneous urticaria. Journal of dermatology. 48 (1), pp. 56-63. [Online]. 
  
Back to record